Results 101 to 110 of about 9,921 (221)

Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS-mutant cancer. [PDF]

, 2021
KRAS oncoprotein is commonly mutated in human cancer, but effective therapies specifically targeting KRAS-driven tumors remain elusive. Here, we show that combined treatment with fibroblast growth factor receptor 1 (FGFR1) and polo-like kinase 1 (PLK1 ...
Thomas M Marti, Deng, Haibin, Haitang Yang, Tschan, Mario, Hegedüs, Balazs, Maria Saliakoura, Wang, Wenxiang, Schmid, Ralph A, Mario Tschan, Liang, Shun-Qing, Liang Zhao, Wenxiang Wang, Vassella, Erik, Ralph A Schmid, Georgia Konstantinidou, Saliakoura, Maria, Peng, Ren-Wang, Marti, Thomas M, Gregor J Kocher, Gao, Yanyun, Kocher, Gregor J, Balazs Hegedüs, Xu, Duo, Ren‐Wang Peng, Yanyun Gao, Eric Vassella, Duo Xu, Haibin Deng, Shun‐Qing Liang, Zhao, Liang, Yang, Haitang, Zhang Yang, Yang, Zhang, Konstantinidou, Georgia   +33 more
core   +2 more sources

AURKA and PLK1 inhibition selectively and synergistically block cell cycle progression in diffuse midline glioma

iScience, 2022
Summary Diffuse midline gliomas (DMG) are highly malignant incurable pediatric brain tumors. In this study, we show that Aurora kinase A (AURKA) is overexpressed in DMG and can be used as a therapeutic target. Additionally, AURKA inhibition combined with
D. Metselaar, Aimée du Chatinier, M. Meel, Giovanna Ter Huizen, Piotr Waranecki, Joshua R. Goulding, M. Bugiani, J. Koster, G. Kaspers, E. Hulleman   +9 more
semanticscholar   +1 more source

PLK1 and FoxM1 expressions positively correlate in papillary thyroid carcinoma and their combined inhibition results in synergistic anti‐tumor effects

Molecular Oncology
Polo‐like kinase 1 (PLK1; also known as serine/threonine‐protein kinase PLK1) serves as a central player in cell proliferation, exerting critical regulatory roles in mitotic processes and cell survival. We conducted an analysis of PLK1 protein expression
Pratheesh Kumar Poyil, Abdul K. Siraj, Divya Padmaja, Sandeep Kumar Parvathareddy, Saravanan Thangavel, Khadija Alobaisi, Roxanne Diaz, Rafia Begum, Wael Haqawi, Saif S. Al‐Sobhi, Fouad Al‐Dayel, Khawla S. Al‐Kuraya   +11 more
doaj   +1 more source

Carrier‐free self‐assembled nanomedicine for combination‐therapy of acute myeloid leukemia

BMEMat, EarlyView.
CPDS combines drugs with three different mechanisms of action to achieve a multi‐mechanism combination therapy for AML by directly killing tumor cells and activating anti‐tumor immunity. Abstract As the main acute myeloid leukemia (AML) clinical treatment, the chemotherapy alone cannot meet the clinical therapeutic needs due to the high heterogeneity ...
Meihong Chai, Rui Zhang, Haiyin Yang, Jiyue Xing, Tianyuan Hu, Mengxi Zhu, Rui Li, Xiaoli Chen, Beibei Zhao, Yang Lan, Stefan Barth, Yuanyu Huang, Li Zhang, Mengjie Zhang, Huining He   +14 more
wiley   +1 more source

BUB1 and CENP-U, Primed by CDK1, Are the Main PLK1 Kinetochore Receptors in Mitosis

Molecules and Cells, 2020
Summary Reflecting its pleiotropic functions, Polo-like kinase 1 (PLK1) localizes to various sub-cellular structures during mitosis. At kinetochores, PLK1 contributes to microtubule attachments and mitotic checkpoint signaling.
Priyanka Singh, M. Pesenti, S. Maffini, S. Carmignani, Marius Hedtfeld, A. Petrovic, Anupallavi Srinivasamani, Tanja Bange, A. Musacchio   +8 more
semanticscholar   +1 more source

PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition

Scientific Reports
The overexpression of Polo-like kinase 1 (PLK1) is associated with poor clinical outcomes in various malignancies, making it an attractive target for anticancer therapies. Although recent studies suggest PLK1’s involvement in homologous recombination (HR)
Sookhee Pae, Anna S. Sedukhina, Runa Sugiyama, Sarah J. Atanacio, Tatsuru Ohara, Masato Ishii, Kimino Minagawa, Romaan Akichjev, Fumie Go, Zayan Chandankeri, Zoran M. M. Janjetic, Eri Sato, Ayako Yamaura, Rei Meguro, Kishore Palanisamy, Ichiro Maeda, Osamu Takeuchi, Nao Suzuki, Kazuo Yudo, Juan A. Bernal, Ko Sato   +20 more
doaj   +1 more source

PLK1 Signaling in Breast Cancer Cells Cooperates with Estrogen Receptor-Dependent Gene Transcription

Cell Reports, 2013
Polo-like kinase 1 (PLK1) is a key regulator of cell division and is overexpressed in many types of human cancers. Compared to its well-characterized role in mitosis, little is known about PLK1 functions in interphase.
Michael Wierer, Gaetano Verde, Paola Pisano, Henrik Molina, Jofre Font-Mateu, Luciano Di Croce, Miguel Beato   +6 more
doaj   +1 more source

Microtubule Destabilizing Kinesins: A Historical Perspective and Thoughts for the Future

Cytoskeleton, EarlyView.
ABSTRACT The microtubule cytoskeleton plays critical roles in multiple cellular processes such as mitotic spindle assembly and chromosome segregation. Cells contain a number of microtubule‐associated proteins that regulate microtubule dynamics both temporally and spatially in cells. The microtubule depolymerizing kinesins include members of the Kinesin‐
Claire E. Walczak
wiley   +1 more source

Anticancer potential of berberine: Molecular pathways and current clinical trial perspectives

JSFA reports, EarlyView.
Abstract Cancer is constantly rising mortality rates due to its late prognosis, poor management, and expensive treatment. Multi‐sectoral approaches for cancer management include hygienic practices, synthetic drug exploitation, radiation therapy, and diet modifications.
Muhammad Maaz, Muhammad Tauseef Sultan, Muhammad Israr, Waqas Ahmad Khan, Fahad Tanveer, Muzzamal Hussain, Muhammad Imran, Ahmed Mujtaba, Anjuman Gul Memon, Muhammad Atif, Entessar Al Jbawi   +10 more
wiley   +1 more source

The balance of Polo-like kinase 1 in tumorigenesis

Cell Division, 2009
Polo-like kinase 1 (Plk1) belongs to a family of conserved serine/threonine kinases with a polo-box domain, which have similar but non-overlapping functions in the cell cycle progression. Plk1 plays a key role to ensure the normal mitosis. Interestingly,
Yu Xiaochun, Lu Lin-Yu
doaj   +1 more source